Malin investee Sanofi discontinues amlitelimab in atopic dermatitis
The decision follows a strategic assessment; safety and efficacy data did not show meaningful improvement over standard of care. No impact on Sanofi's 2026 guidance.
See the latest news and media coverage for Malin. We track all announcements, press releases, and industry mentions in real time, all in one place.
Publicly listed life sciences investment company
malinplc.comLast updated
In short: Malin Corporation reduced its investment portfolio and returned €150 million to shareholders as its chief executive stepped down.
The decision follows a strategic assessment; safety and efficacy data did not show meaningful improvement over standard of care. No impact on Sanofi's 2026 guidance.
Amlitelimab met key endpoints in SHORE and COAST 2 studies for atopic dermatitis treatment. Sanofi plans global regulatory submissions in H2 2026.
The VIOLET Phase 3 extension study showed 98% of women remained infection-free versus 82% on placebo for nearly two years. VIVJOA is FDA-approved for RVVC in non-reproductive potential women.
The offer at €10.30 per share closes 20 March 2025, pending shareholder approval at EGM on 13 March 2025.
Malin Corporation will receive less than 80 per cent of the $33 million (€29 million) in earnout payments tied to the 2021 sale of its...
Malin Corporation plc, the Ireland-based life sciences investment company listed on Euronext Growth Dublin, targets innovative healthcare businesses worldwide, backing firms built on strong scientific...
The Iseq All Share ended Tuesday trading up nearly 3 per cent, with Bank of Ireland... February was a month of two halves for investors...
Malin Corporation said its chief executive Fiona Dunlevy is leaving the Dublin-listed life sciences investment company as the value of its investments shrank by 80...
Track Malin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Malin and other trending companies.